Abstract
Background Dengue virus, a major global health threat, consists of four serotypes (DENV1-4) that cause a range of clinical manifestations from mild to severe and potentially fatal disease.
Methods This study, based on 19 years of data from the Pediatric Dengue Cohort Study and Pediatric Dengue Hospital-based Study in Managua, Nicaragua, investigates the influence of serotype and immune status on dengue severity. Study participants 6 months to 17 years old were followed during their hospital stay or as ambulatory patients, with dengue cases confirmed by molecular, serological, and/or virological methods.
Results We enrolled a total of 14071 participants, of whom 2954 (21%) were positive for DENV infection. Of 2425 cases with serotype result by RT-PCR, 541 corresponded to DENV1, 996 to DENV2, 718 to DENV3 and 170 to DENV4. Severe disease was more prevalent among secondary DENV2 and DENV4 cases, while similar disease severity was observed in both primary and secondary DENV1 and DENV3 cases. According to the 1997 World Health Organization (WHO) severity classification, both DENV2 and DENV3 had a higher proportion of severe disease compared to other serotypes, whereas DENV3 had the greatest percentage of severity under the WHO-2009 classification. DENV2 was associated with pleural effusion and low platelet count, while DENV3 correlated with both hypotensive and compensated shock.
Conclusions These findings emphasize the critical need for a dengue vaccine with balanced efficacy against all four serotypes, particularly as existing vaccines show variable efficacy by serotype and immune status, posing challenges for comprehensive protection, particularly in dengue-naïve individuals.
Summary We analyzed dengue virus (DENV) disease severity stratified by serotype and immune status over 19 years of two pediatric studies in Nicaragua. DENV2 and DENV3 caused the most severity – primarily secondary DENV2 cases and both primary and secondary DENV3 cases.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Institute for Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) grant numbers P01 AI106695 (EH) and R01 AI099631 (AB). The studies were supported by P01 AI106695 (EH), U01 AI153416 (EH), U19 AI118610 (EH), R01 AI099631 (AB), U54 AI65359 (Barbour; subcontract AB), and BAA-NIAID-DAIT-NIHAI2009061 (Loeb; subcontract AB) from NIAID/NIH, and the the Pediatric Dengue Vaccine Initiative grant VE-1 (EH) and the FIRST grant (EH) from the Bill and Melinda Gates Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics IRB of the Nicaraguan Ministry of Health (Protocol #CIRE-09/03/07-008.Ver24, CIRE-01/10/06-13.ver8) and the University of California Berkeley Committee for the Protection of Human Subjects (Protocols 2010-09-2245, 2010-06-1649) gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
After securing approval from the UC Berkeley Committee for the Protection of Human Subjects, individual data for figure reproduction can be shared with external researchers. For data access arrangements, please contact E.H. at eharris@berkeley.edu or the CPHS at ophs@berkeley.edu. Standard data transfer agreements govern all data used in this study.
https://github.com/jgjuarez/Narvaez_Dengue_Clinical_Severity
